
Paul De Leyn¹, Christophe Dooms², Jaroslaw Kuzdzal³, Didier Lardinois⁴, Bernward Passlick⁵, Ramon Rami-Porta⁶, Akif Turna⁷, Paul Van Schil⁸, Frederico Venuta⁹, David Waller¹⁰, Walter Weder¹¹, Marcin Zielinski¹²

1Department of Thoracic Surgery, 2Department of Pneumology, University Hospitals Leuven, Leuven, Belgium; ³Department of Thoracic Surgery, Jagiellonian University, Collegium Medicum, Krakow, Poland; 4Division of Thoracic Surgery, University Hospital Basel, Basel, Switzerland; 5Department of Thoracic Surgery, Albert-Ludwigs-University Freiburg, Freiburg, Germany; 6Department of Thoracic Surgery, University Hospital Mutua de Terrassa and CIBERES Lung Cancer Group, Terrassa, Barcelona, Spain; 7Department of Thoracic Surgery, University Hospital Istanbul, Istanbul, Turkey; 8Department of Thoracic and Vascular Surgery, Antwerp University Hospital, Edegem, Belgium; 9Department of Thoracic Surgery, Sant Andrea Hospital, University of Rome La Sapienza, Rome, Italy; 10Department of Thoracic Surgery, Glenfield Hospital, Leicester, UK; 11Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland; 12Department of Thoracic Surgery, Pulmonary Hospital, Zakopane, Poland

Correspondence to: Paul De Leyn, MD, PhD. Department of Thoracic Surgery, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium. Email: Paul.Deleyn@uzleuven.be.

Abstract: Accurate preoperative staging and restaging of mediastinal lymph nodes in patients with potentially resectable non-small cell lung cancer (NSCLC) is of paramount importance. In 2007, the European Society of Thoracic Surgeons (ESTS) published an algorithm on preoperative mediastinal staging integrating imaging, endoscopic and surgical techniques. Over the last years more evidence of the different mediastinal staging technique has become available. Therefore, a revision of the ESTS guidelines was needed. In case of CT-enlarged or PET-positive mediastinal lymph nodes, tissue confirmation is indicated. Endosonography (EBUS/EUS) with fine needle aspiration is the first choice (when available) since it is minimally invasive and has a high sensitivity to rule in mediastinal nodal disease. If negative, surgical staging with nodal dissection or biopsy is indicated. Video-assisted mediastinoscopy is preferred over mediastinoscopy. The combined use of endoscopic staging and surgical staging results in the highest accuracy. When there are no enlarged lymph nodes on CT and when there is no uptake in lymph nodes on PET or PET-CT, direct surgical resection with systematic nodal dissection is indicated for tumors ≤3 cm located in the outer third of the lung. In central tumors or N1 nodes, preoperative mediastinal staging is indicated. The choice between endoscopic staging with EBUS/EUS and fine needle aspiration or video-assisted mediastinoscopy depends on local expertise to adhere to minimal requirements for staging. For tumors larger than 3 cm, preoperative mediastinal staging is advised, mainly in adenocarcinoma with high SUV uptake.

Keywords: Lung cancer; preoperative staging; surgical staging; endoscopic staging

Submitted Jul 07, 2014. Accepted for publication Aug 08, 2014.
doi: 10.3978/j.issn.2218-6751.2014.08.05
View this article at: http://dx.doi.org/10.3978/j.issn.2218-6751.2014.08.05

Introduction

For patients with non-small cell lung cancer (NSCLC) and no systemic metastasis, mediastinal staging is very important as it provides accurate information on the extent of the disease, it guides the choice of treatment and determines the patient’s prognosis.

In 2007, the European Society of Thoracic Surgeons (ESTS) published an algorithm on preoperative mediastinal staging based on the current available literature (1). These guidelines integrated imaging, endoscopic and surgical techniques. They were widely used and have been prospectively validated. Their negative predictive value is 0.94 (2).
New insights on the importance of restaging and techniques for mediastinal restaging have become available. Therefore, the ESTS Council approved the initiative by the working group to revise and update the previous guidelines on mediastinal staging.

**Methodology**

There were several meetings of the working group. The project was discussed in the Council at the ESTS meeting in Essen (June 2012). There were several meetings (Essen, Zürich, Brussels and Birmingham) where the participants presented their experience and discussed the relevant literature published since 2007. Initial findings were presented and discussed at the ESTS meeting in Birmingham (May 2013). The final paper was put on the website for discussion by all ESTS members. Their remarks were discussed and included in the final manuscript.

For recommendations, a level of evidence and grading of recommendation is given. This was adapted from the Infectious Disease Society of American-United States Public Health Service Grading System (Table 1) (3).

<table>
<thead>
<tr>
<th>Level</th>
<th>Type of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Evidence from at least one large randomized control trial of good methodological quality (low potential for bias) or meta-analyses of well-conducted randomized trials without heterogeneity</td>
</tr>
<tr>
<td>II</td>
<td>Small randomized trials or large randomized trials with a suspicion of bias (lower methodological quality) or meta-analyses of such trials or trials with demonstrated heterogeneity</td>
</tr>
<tr>
<td>III</td>
<td>Prospective cohort studies</td>
</tr>
<tr>
<td>IV</td>
<td>Retrospective cohort studies or case-control studies</td>
</tr>
<tr>
<td>V</td>
<td>Studies without control group, case reports, experts opinions</td>
</tr>
<tr>
<td>A</td>
<td>Strong evidence for efficacy with a substantial clinical benefit, strongly recommended</td>
</tr>
<tr>
<td>B</td>
<td>Strong or moderate evidence for efficacy but with a limited clinical benefit, generally recommended</td>
</tr>
<tr>
<td>C</td>
<td>Insufficient evidence for efficacy or benefit does not outweigh the risk or the disadvantages (adverse events, costs), optional</td>
</tr>
<tr>
<td>D</td>
<td>Moderate evidence against efficacy or for adverse outcome, generally not recommended</td>
</tr>
<tr>
<td>E</td>
<td>Strong evidence against efficacy or for adverse outcome, never recommended</td>
</tr>
</tbody>
</table>

The aim of mediastinal staging is to exclude with the highest certainty and the lowest morbidity patients with mediastinal nodal disease since these patients will not benefit from upfront surgery (4,5).

There is controversy regarding the best treatment of N2 disease because of the heterogeneity of nodal involvement. Also patient and tumour characteristics and extent of resection plays a role in the selection of treatment modality for these patients.

There is a subgroup of patients with pretreatment histologically proven N2 disease who are candidate for surgical multimodality treatment. These patients are treated with induction chemotherapy or induction chemoradiotherapy. In case of downstaging of the mediastinal lymph nodes or major response in those lymph nodes and in the tumour, resection with systematic nodal dissection can be performed with acceptable morbidity and mortality and rewarding 5-year survival. There are several prognostic indicators, some of them are related to the primary tumour and others are related to the extent of nodal disease. To include patients for surgical multimodality treatment, the disease should be initially technically resectable. Excluded for surgical multimodality are patients with unresectable disease such as extracapsular disease (can be clearly visualized by mediastinoscopy), or bulky N2 disease based on CT. Fit patients with extracapsular disease and/or bulky N2 disease should be treated with definitive chemoradiotherapy.

Bulky N2 disease is not well defined but it correlates with the radiographic group A, as described in the American College of Chest Physicians (ACCP) Evidence-based Clinical Practice Guidelines (6). This group is defined as...
mediastinal infiltration where the discrete lymph nodes cannot be distinguished or measured. Bulky is not strictly related to the size of the lymph nodes, but it is considered by this committee that lymph nodes larger than 25 mm short axis will also be defined as bulky disease (level V). Bulky disease can be restricted to a single station but usually represents multistation or multiple zonal involvement. Since this paper deals with preoperative lymph node staging, techniques to obtain histology in bulky mediastinal nodal disease are beyond the scope of this article.

Preoperative mediastinal lymph node staging

Several techniques are available and their use depends on local availability and local expertise.

These techniques include:
(I) Imaging techniques;
(II) Endoscopic techniques;
(III) Surgical techniques.

Although we should aim for the test with the highest sensitivity and NPV, the working group considers a rate of unforeseen pN2 disease of 10% as acceptable. After thorough mediastinal staging this unforeseen pN2 is mostly single station resectable nodal disease.

Imaging techniques

Chest CT-scan

Computed tomography remains important in lung cancer imaging. However, due to its low sensitivity (55%) and specificity (81%) it is impossible to solely rely on CT-scan (6). CT-scan may help us in selecting the appropriate procedure for tissue sampling due to the anatomical images it provides.

PET-CT scan

The addition of PET to CT results in more accurate lymph node staging than CT alone with an overall sensitivity of 80-90% and specificity of 85-95%. PET-CT has a high NPV for detecting mediastinal nodal disease in peripherally located NSCLC. Exceptions include:
(I) Suspected N1 nodes;
(II) Tumour >3 cm;
(III) Centrally located tumour without suspected nodes on CT or PET scan.

In a study from Japan (7), 30% of 143 patients with N1 disease on CT-scan (lymph node short axis >1 cm) were found to have pathologic N2-N3.

A recent meta-analysis (8) has shown that the negative predictive value of PET-CT for tumours ≤3 cm was 94% (649 patients) compared to 89% for tumours >3 cm (130 patients) staged as T2 (6th edition of TNM). This finding was confirmed in a recent prospective study from Spain (9). For peripheral tumours ≤3 cm the negative predictive value of PET-CT was 92% while it was 85% for tumours >3 cm. Based on these studies, we now recommend that for peripheral tumours (outer third of the lung) ≤3 cm without enlarged (hilar and/or mediastinal) lymph nodes on CT and with PET-negative nodes, further mediastinal staging can be omitted. There was a substantial difference in rate of mediastinal nodal disease between adenocarcinoma and other tumour histology (risk ratio 2.72). Also high FDG uptake in the primary lesion was associated with greater risk of occult nodal metastasis. For tumours >3 cm (mainly adenocarcinoma with high FDG uptake) further mediastinal staging techniques providing histology should be considered.

Lee et al. (10) examined the prevalence of pathologic N2 disease in patients with clinical stage I NSCLC (6th edition of TNM version) with negative mediastinum on PET and CT. In 2.9% of peripheral tumours (outer third of lung) N2 disease was found, while the prevalence of N2 disease was 21.6% in central tumours.

Diffusion-weighted magnetic resonance imaging

Advances in MRI technology have allowed acquisition of diffusion-weighted MRI (DWI), which provides excellent tissue contrast because of the difference in the diffusion of water molecules among tissues. The technique yields qualitative and quantitative information that reflects changes at a cellular level and provides unique insights about tumour cellularity and the integrity of cell membranes. In a recent meta-analysis (11) the accuracy of DWI and 18F-FDG PET/CT was evaluated. The pooled sensitivity for DWI was 0.95 (95% CI, 0.85-0.98) and significantly better than for FDG-PET/CT 0.89 (89% CI, 0.85-0.91). However, at this moment there are no large prospective studies comparing the value of DWI and FDG-PET and it is too early to determine the true value of DWI in nodal staging in patients with NSCLC.

Endoscopic techniques

Conventional TBNA

Although the conventional TBNA technique has been
available for almost three decades, its use in routine clinical practice has only been adopted by a minority (10-15%) of pulmonologists for mediastinal nodal staging of patients with potentially resectable stage I-III lung cancer. Major reasons for its underuse are its dependency on nodal size (>15-20 mm short axis on CT scan) and operator skills. Meta-analyses reported a sensitivity of 78% and a false negative rate of 28% for conventional TBNA in clinical N2 disease with high disease prevalence of 81% (12,13). A conventional blind TBNA is useful if it leads to proof of N3 disease, but too often does not exclude N3 disease in cases of proven N2 disease.

**Endoscopic ultrasonography: EUS-FNA and EBUS-TBNA**

**Practical aspects**

Although E(B)US-TBNA is performed in some centers under general anesthesia, EBUS and EUS are more often performed in an outpatient setting under local anesthesia with moderate sedation.

EBUS is able to visualise superior and inferior mediastinal LNs at stations 2R/2L, 4R/4L and 7, as well as hilar LNs at stations 10, 11, and even 12, as described on the new LN map (14). EUS particularly visualises superior mediastinal lymph nodes in station 4L, and inferior mediastinal nodes in stations 7, 8 and 9, as described on the new LN map (Rusch 2009). Thus, EUS-FNA complements other techniques, as several of these LNs (stations 8 and 9) are not accessible by EBUS-TBNA or mediastinoscopy. Although some expert centres considered EUS-FNA of lymph nodes in stations 5 or 6, currently available data are limited and therefore we do not recommend routine use of this procedure for this indication (15).

It is possible to visualize and sample lymph nodes with a short axis of >5 mm and the optimal number of aspirations per station has been reported to be three (16). When mediastinal nodal staging is required, systematic nodal sampling is feasible by endosonography. Indeed, several endosonography series have shown a mean or median number of sampled mediastinal nodal stations of 3 to 4 per patient (17-22). Nodal stations 4R, 4L, and 7 should always be sought during the endosonographic examination and described in the medical report. In addition the largest node measuring >5 mm on ultrasonography within each of these stations as well as FDG avid nodes within each of these nodal stations should be sampled for pathological analysis. On indication nodal station 10R and 10L can be biopsied. To avoid contamination while using one single needle for an EBUS or EUS procedure, the order of nodal sampling should begin at the level of N3 nodes followed by N2 nodes before ending with N1 nodes.

**Performance characteristics**

Several meta-analyses on EUS-FNA alone, EBUS-TBNA alone, and combined EUS+EBUS reported a pooled sensitivity of 83% to 94% for mediastinal staging of lung cancer (Table 2) (23-27). Only one randomized controlled trial (Aster trial, 17) has been performed, comparing the two staging strategies proposed in the ESTS 2007 guidelines (either mediastinoscopy, or alternatively endosonography followed by mediastinoscopy) (1). There was no difference in sensitivity or NPV when mediastinoscopy was compared with endoscopic staging. However, the staging strategy starting with combined endosonography and if negative combining it with surgical staging has proven to detect significantly more mediastinal nodal N2/3 disease compared to mediastinoscopy alone (17). Another consequence is that the implementation of endosonography for baseline mediastinal nodal staging clearly reduces the need for mediastinoscopy (28). On the other hand, the negative likelihood ratio reported by three of the

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Modality</th>
<th>Pts (N)</th>
<th>Pooled sens % (95% CI)</th>
<th>Pooled spec % (95% CI)</th>
<th>NLR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Micames, et al. (23)</td>
<td>2007</td>
<td>EUS</td>
<td>1,201</td>
<td>83 [78-87]</td>
<td>97 [96-98]</td>
<td>–</td>
</tr>
<tr>
<td>Gu, et al. (24)</td>
<td>2009</td>
<td>EBUS</td>
<td>1,298</td>
<td>93 [91-94]</td>
<td>100 [99-100]</td>
<td>–</td>
</tr>
<tr>
<td>Adams, et al. (25)</td>
<td>2009</td>
<td>EBUS</td>
<td>817</td>
<td>88 [79-94]</td>
<td>100 [92-100]</td>
<td>0.12</td>
</tr>
<tr>
<td>Chandra, et al. (26)</td>
<td>2012</td>
<td>EBUS</td>
<td>1,658*</td>
<td>92 [90-93]</td>
<td>100 [97-100]</td>
<td>0.13</td>
</tr>
<tr>
<td>Zhang, et al. (27)</td>
<td>2013</td>
<td>EUS + EBUS</td>
<td>823</td>
<td>86 [82-90]</td>
<td>100 [99-100]</td>
<td>0.15</td>
</tr>
</tbody>
</table>

N, number; CI, confidence intervals; EUS, esophageal endosonograph; EBUS, endobronchial endosonography; Pts, patients; Sens, sensitivity; Spec, specificity; NLR, negative likelihood ratio; *, some small series also included sarcoidosis.
meta-analyses is 0.13 to 0.15 (Table 2) (25-27). This implies that the probability of having mediastinal nodal involvement for any individual patient with a negative endosonography result is 13-15%. This probability based on endosonography alone is in our opinion not low enough to directly proceed to a surgical resection. Therefore in the routine practice we still recommend a preoperative surgical staging procedure (i.e., VAM) in case of a negative endosonography. However, there is evidence coming from prospective studies performed in experienced endosonography centres, that mediastinoscopy may not improve sensitivity after a well-performed negative endosonography with needle aspiration of at least three mediastinal nodal stations in patients with low (<35%) prevalence of mediastinal disease (18,29,30). EBUS-TBNA and EUS-FNA are safe procedures with reported minor complications in <1% of cases (23,24,31). With the rapidly increasing number of procedures, occasional reports of moderate to severe complications have been published, such as pneumothorax requiring chest tube drainage, infection of bronchogenic cyst, empyema, lung and/or mediastinal abscess, and haemopneumomediastinum are published. So far, only one death has been reported related to an EBUS-TBNA procedure (32).

### Surgical staging techniques

#### Cervical mediastinoscopy

Cervical mediastinoscopy through a pretracheal suprasternal incision was introduced by Carlens in 1959 and further popularized by Pearson in North America. It allows a full mapping of the ipsilateral and contralateral superior mediastinal lymph nodes. Cervical mediastinoscopy is performed under general anaesthesia and can be safely done as an outpatient procedure. For many years it was the gold standard for invasive staging of patients with potentially operable lung cancer. Since 1995, use of video techniques has been introduced leading to video-assisted mediastinoscopy (VAM). VAM clearly improved visualization and teaching (33) since both the trainer and the trainee can share the magnified image on the monitor. For more details on the technique of cervical mediastinoscopy, we refer to a recent publication on this topic (34).

There are only retrospective studies comparing the safety and accuracy of conventional mediastinoscopy with VAM. Although some authors (35-37) found an increase in the number of LN or LN stations biopsied, no difference in sensitivity or NPV was found. In some of these studies a reduction in the complication rate (mainly of recurrent nerve palsy) was observed. Very recently (38), a best evidence topic has been published on the safety and accuracy of VAM compared to conventional mediastinoscopy (Table 3). The authors analysed 108 papers published between 1989 and 2011. There were 5,156 conventional mediastinoscopies and 956 VAMs. Both procedures are safe with no mortality in that time frame and a low morbidity. Although by VAM more lymph node stations are sampled, the negative predictive value and accuracy were identical.

Although the video-mediastinoscope is not strictly necessary to achieve a thorough, clinically acceptable mediastinoscopy, it has many advantages over the conventional one: larger and clearer images, the possibility to simultaneously share the procedure with trainees and all the personnel in the operative theatre, the possibility to record the operation for future educational uses and discussion, and the possibility to improve its teaching without compromising the safety or accuracy of the procedure. Moreover it allows bimanual dissection with possibilities to perform nodal dissection and removal rather than sampling or biopsy. This is especially important and technically feasible for the subcarinal LN station. After removal of station 7 LNs, the oesophagus can be
clearly visualized. The ESTS working group recommends performing VAM.

**Video-assisted thoracoscopic surgery (VATS)**

Although VATS can reach almost every mediastinal lymph node station, it is more invasive than cervical mediastinoscopy (it needs double lumen intubation), it is limited by pleural adhesions, and it can only evaluate ipsilateral nodal disease. For the para-aortic lymph nodes (station 6) and the subaortic lymph nodes (station 5), left VATS is a surgical technique that allows obtaining large tissue samples. It is indicated when enlarged PET positive lymph nodes are visualized at level 5 or 6. These lymph node stations cannot be biopsied by routine mediastinoscopy, E(B)US-FNA. An alternative to VATS is the left anterior mediastinotomy. In some experienced centres, extended mediastinoscopy from the mediastinoscopy incision is performed for these lymph node stations and it gives good negative predictive values: 0.89-0.97 (34).

**Video-assisted mediastinoscopic lymphadenectomy (VAMLA) transcervical extended mediastinal lymphadenectomy (TEMLA)**

During the last decade, two new invasive staging techniques representing more radical methods of mediastinal exploration have been introduced: VAMLA (39) and TEMLA (40). These two techniques aim for a complete removal of all the mediastinal nodes with the surrounding adipose tissue to improve the accuracy of staging. VAMLA is completely performed with the use of the videomediastinoscope whilst TEMLA uses a 5-8 cm collar incision in the neck and elevates the sternum with a hook. The dissection is performed in an open way and with the use of the videomediastinoscope. By VAMLA, the lymph nodes which are usually accessible through mediastinoscopy, are removed. By TEMLA, more lymph node stations are accessible such as the prevascular, the para-aortic, the subaortic and the para-oesophageal lymph node stations. The negative predictive value is very high and approaches 98.7% for TEMLA. Although there is no doubt that the accuracy of mediastinal staging increases when lymphadenectomy is performed compared to nodal biopsy, these techniques have a higher morbidity and mortality. The complications after VAMLA and TEMLA are well recorded and are probably more studied in detail than after CM or VAM. These procedures are performed in very experienced centres. For VAMLA mainly problems with recurrent nerve palsy and important scarring with an impact on subsequent resection are reported (39,41-44). The published data for TEMLA are mainly from one very experienced centre and there are concerns on morbidity and mortality.

For TEMLA and VAMLA we conclude that currently available data regarding its use are limited and, therefore, we do not recommend its use except of clinical trials. We encourage other centres to publish their data with these new staging techniques.

The algorithm for preoperative mediastinal staging is shown in **Figure 1**. For NSCLC, both for mediastinal as for distant staging, PET or PET-CT is indicated.

- Direct surgery can be performed if all of these three criteria apply: no suspect lymph node detected by CT or PET, a tumor ≤3 cm (stage IA), located in the outer third of the lung (level IIA).
- In case of enlarged mediastinal lymph nodes on CT or PET-positive lymph nodes, tissue confirmation is indicated. In this case, endosonography (EBUS/EUS) with fine needle aspiration is the first choice (when available) since it is minimally invasive and has a high sensitivity to rule in mediastinal nodal disease (level IA). If negative, video-assisted mediastinoscopy is indicated (level IB). The combined use of endoscopic staging and surgical staging results in the highest accuracy.

For patients with a left upper lobe tumour, surgical staging of the aorto-pulmonary window nodes (if enlarged on CT and/or PET-CT-positive) can be performed (by anterior mediastinotomy, VATS or extended cervical mediastinoscopy) if involvement changes treatment strategy (level V).

- Invasive staging by E(B)US/mediastinoscopy is indicated if at least one of these criteria apply: central lesion, suspect N1 nodes (level IIB). In case of tumors >3 cm (mainly in adenocarcinoma with high FDG uptake) the negative predictive value for mediastinal nodal disease is <90% and invasive staging may be considered (level IIB). Although a high FDG update in the primary tumor is a predictor of N2 disease, the ideal cutoff of SUV value has not yet been determined above which invasive mediastinal nodal staging is required. In addition, the SUV measurement is not yet standardized from one center to another and therefore a visual interpretation of the FDG uptake on PET is to be preferred (Dooms 2010). In all of the above-mentioned cases there is
the choice between VAM with biopsy or lymph node dissection or endoscopic staging by EBUS/EUS with fine needle aspiration. The choice depends on local expertise to adhere to minimal requirements for staging (level V). If video-assisted mediastinoscopy is negative, these patients can undergo surgical treatment. They also can undergo surgical treatment after negative EBUS/EUS if the number of nodes explored and the number of needle passes in each node meet the established requirements. Otherwise, surgical exploration is recommended after negative EBUS/EUS.

- If only CT is available, we refer to the algorithm of the 2007 edition of the ESTS guidelines (De Leyn 2007).

We conclude that optimal mediastinal lymph node staging is a truly multidisciplinary process, with a variety of possible techniques, to be performed by experienced hands.

**Acknowledgements**

**Disclosure:** The authors declare no conflict of interest.

**References**


